Clinical Trial Update: Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of naxitamab plus GM-CSF in combination with intratumoral therapy in high-risk neuroblastoma was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Naxitamab (naxitamab)

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: Neuroblastoma Recurrent | Phase 2 | Status: TERMINATED | Results posted: 2024-03-18